三例非小细胞肺癌罕见胚系与体细胞EGFR变异的临床与功能特征
该研究在德国基因组医学网络Task Force 5中对非小细胞肺癌患者行胚系全基因组测序,发现三个患者携带两种不同的EGFR胚系变异,并各合并不同的体细胞复合变异。体外Ba/F3模型显示这些复合变异具有致癌活性且对阿法替尼敏感,两名患者临床获得部分缓解,提示胚系EGFR变异解读需结合功能分析。
要点
- 三个NSCLC患者检出两种EGFR胚系变异,均合并不同体细胞复合变异。
- Ba/F3实验显示复合变异有致癌活性且对阿法替尼敏感,两例患者部分缓解。
- 胚系EGFR变异的功能学解读有助于风险预测与靶向治疗选择。
核心结论
- 胚系EGFR变异在NSCLC中具有临床相关性,结合in silico与in vitro分析有助于变异解读和疗效预测。
研究设计与样本
- 在德国国家基因组医学网络Task Force 5中对NSCLC患者行胚系全基因组测序,检出的EGFR变异进一步用in silico结构建模和Ba/F3细胞体外功能表征。
主要发现
- 三个NSCLC患者中检出两种EGFR胚系变异:NM_005228.5:c.2155G>A p.(Gly719Ser)和NM_005228.5:c.2327G>A p.(Arg776His)。
- 每位患者各携带不同的体细胞复合变异:p.(Gly719Ser)+p.(Ser768Ile)、p.(Gly719Ala)+p.(Arg776His)、p.(Arg776His)+p.(Leu861Gln)(肝转移)及p.(Arg776His)+p.(Gly719Ser)。
- In silico分析预测p.(Gly719Ser)和p.(Gly719Ala)稳定EGFR激酶活性构象,而p.(Ser768Ile)、p.(Arg776His)和p.(Leu861Gln)去稳定非活性构象。
- Ba/F3实验中复合变异的顺式共表达显示致癌活性并对阿法替尼敏感,临床上两名个体对阿法替尼治疗获得部分缓解。
临床怎么用
- 对NSCLC患者可考虑扩大胚系检测以识别EGFR等遗传易感变异。
- 对罕见EGFR变异应结合in silico与in vitro功能分析辅助解读和靶向治疗决策。
局限性
- 研究仅基于三个患者,样本量有限,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date hereditary risk factors for non-small cell lung cancer (NSCLC) are poorly understood. While most cases are considered sporadic, rare monogenic germline alterations in EGFR and TP53 have been reported to be associated with increased risk of NSCLC. While identification and accurate functional characterization of such variants are essential for improving risk assessment and personalized therapeutic strategies, they remain limited. Germline whole genome sequencing (WGS) was performed to identify potential hereditary causes of NSCLC within Task Force 5 of the German National Network for Genomic Medicine. Detected EGFR variants were further investigated using in silico structural modeling and in vitro functional characterization in Ba/F3 cell models to investigate their oncogenic potential and sensitivity to tyrosine kinase inhibitors (TKIs). We identified two different EGFR germline variants (NM_005228.5:c.2155G>A, p.(Gly719Ser); NM_005228.5: c.2327G>A, p.(Arg776His)) in three patients with NSCLC, each harboring a different somatic compound variants (p.(Gly719Ser)+p.(Ser768Ile), p.(Gly719Ala)+p.(Arg776His), p.(Arg776His)+p.(Leu861Gln) (liver metastasis) and p.(Arg776His)+p.(Gly719Ser)). In silico analyses predict that p.(Gly719Ser) and p.(Gly719Ala) stabilize the active EGFR kinase conformation, whereas p.(Ser768Ile), p.(Arg776His) and p.(Leu861Gln) destabilize the inactive conformation. Consistent with these predictions, cis co-expression of the compound variants in the Ba/F3 assay demonstrated oncogenic activity and sensitivity to afatinib. Clinically two individuals achieved a partial response to afatinib treatment. These findings highlight the clinical relevance of germline EGFR variants in NSCLC and support the value of in-silico and in-vitro analyses for variant interpretation and response prediction. Broadening germline testing and functional variant characterization may enhance risk prediction and targeted therapy for individuals with NSCLC.
引用
- Prielipp R, Albers-Leischner C, Sharapova Y, et al. Brief report: Clinical and Functional Characterization of Rare Germline and Somatic EGFR Variants in Three Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2026. PMID: 42962921. doi:10.1016/j.jtho.2026.106222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。